Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/17/22
End: 12/20/23
Due: 12/20/24
Phase: N/A
Priority: Normal
Start: 12/22/22
End: 12/20/24
Due: 12/20/25
Phase: N/A
Priority: Normal
Start: 01/31/23
End: 01/02/24
Due: 01/02/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis | NCT05655299 | Ventyx Biosciences, Inc | user2@example.com | None | 2022-11-17 | 2023-12-20 | 2024-12-20 | - | - | 2025-07-14 |
| VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease | NCT05688852 | Ventyx Biosciences, Inc | user2@example.com | None | 2022-12-22 | 2024-12-20 | 2025-12-20 | - | - | 2025-07-14 |
| VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) | NCT05715125 | Ventyx Biosciences, Inc | user2@example.com | None | 2023-01-31 | 2024-01-02 | 2025-01-02 | - | - | 2025-07-14 |